Search research articles
Contact Us
Filters
Showing results (151-160 of 159) with videos related to
Page
of 16
Sort By:
You have reached the last page of results.
This site can display upto 159 results.
Breast (Edinburgh, Scotland)
|
October 2, 2024
Clinical significance of serum estradiol monitoring in women receiving adjuvant aromatase inhibitor for hormone receptor-positive early breast cancer
Shuqin Dai, Xingping Wu, Xuefang Huang, et al.
The Lancet. Oncology
|
November 27, 2025
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial
Jing Yuan, Xi-Wen Bi, Xin Hua, et al.
Journal of the National Cancer Institute
|
May 17, 2019
The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial
Yanhong Su, Jiajia Huang, Shusen Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 23, 2021
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
Xin Hua, Xi-Wen Bi, Jian-Li Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 2, 2025
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial
Ruo-Xi Hong, Fei Xu, Wen Xia, et al.
Cancer
|
March 22, 2024
A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study
Meiting Chen, Lu Li, Qing Xia, et al.
Cancer Cell
|
April 11, 2025
Neoadjuvant toripalimab plus nimotuzumab combined with taxol-based chemotherapy in locally advanced penile squamous cell carcinoma
Xin An, Sheng Jie Guo, Ru Yan, et al.
JAMA
|
December 10, 2020
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial
Xi Wang, Shu-Sen Wang, Heng Huang, et al.
Breast Cancer (Dove Medical Press)
|
April 17, 2024
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial
Ying Chen, Wen-Xia Li, Jia-Hua Wu, et al.
Page
of 16
Search research articles
Search
Showing results (151-160 of 159) with videos related to
Sort By:
Page
of 16
You have reached the last page of results.
This site can display upto 159 results.
Breast (Edinburgh, Scotland)
|
October 2, 2024
Clinical significance of serum estradiol monitoring in women receiving adjuvant aromatase inhibitor for hormone receptor-positive early breast cancer
Shuqin Dai, Xingping Wu, Xuefang Huang, et al.
The Lancet. Oncology
|
November 27, 2025
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial
Jing Yuan, Xi-Wen Bi, Xin Hua, et al.
Journal of the National Cancer Institute
|
May 17, 2019
The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial
Yanhong Su, Jiajia Huang, Shusen Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 23, 2021
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
Xin Hua, Xi-Wen Bi, Jian-Li Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 2, 2025
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial
Ruo-Xi Hong, Fei Xu, Wen Xia, et al.
Cancer
|
March 22, 2024
A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study
Meiting Chen, Lu Li, Qing Xia, et al.
Cancer Cell
|
April 11, 2025
Neoadjuvant toripalimab plus nimotuzumab combined with taxol-based chemotherapy in locally advanced penile squamous cell carcinoma
Xin An, Sheng Jie Guo, Ru Yan, et al.
JAMA
|
December 10, 2020
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial
Xi Wang, Shu-Sen Wang, Heng Huang, et al.
Breast Cancer (Dove Medical Press)
|
April 17, 2024
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial
Ying Chen, Wen-Xia Li, Jia-Hua Wu, et al.
Page
of 16